ArticleNature biotechnology2026
Highly multiplexed mammalian metabolic engineering with a shotgun approach.
Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Mammalian metabolic engineering advances basic biology, bioproduction and cell therapy. However, as pathway complexity increases, so does the size of the combinatorial design space and required DNA constructs, rendering unbiased screens intractable. Here, we developed shotgun genetic engineering (SGE), which exploits the ease of delivering many barcoded small constructs-rather than a single large one-into mammalian cells. Each cell serves as an independent experiment, carrying a synthetic pathway that explores gene content, stoichiometry and organellar localization. Functional pathways are identified by sequencing barcodes from cells exhibiting the desired phenotype. Using SGE, we screened millions of pathway combinations to engineer essential amino acid biosynthesis, achieving near-wild-type growth without valine and enabling isoleucine-free growth in Chinese hamster ovary cells, as well as valine-free growth in Jurkat cells. Functional pathways favored mitochondrial localization and required the integration of tens of kilobases of synthetic DNA, beyond the scale of conventional screening. The resulting datasets support machine-learning-guided decoding and engineering of complex biosynthetic traits in mammalian systems.
Identifiers
42839049What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.